Deltona FL 非小细胞肺癌临床试验
15项针对 非小细胞肺癌的研究正在 Deltona及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
招募中1/2 期
- Mid Florida Hematology And Oncology Center /ID# 273777, Orange City · 距离 4 英里
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
招募中3 期
- Mid Florida Hematology and Oncology Center ( Site 0018), Orange City · 距离 4 英里
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
招募中3 期
- Alpha Clinical Research Centers LLC, Orange City · 距离 4 英里
- Florida Cancer Specialists, Orange City · 距离 4 英里
- Mid Florida Hematology and Oncology Center, Orange City · 距离 4 英里
- 以及另外 1 项
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
招募中3 期
- Mid Florida Hematology and Oncology Center, Orange City · 距离 4 英里
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
招募中1/2 期
- Mid Florida Hematology and Oncology Center, Orange City · 距离 4 英里
Pan-tumor MRD Study
招募中观察性研究
- Mid Florida Cancer Centers, Orange City · 距离 4 英里
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
招募中3 期
- Research Site, Orange City · 距离 4 英里
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
招募中3 期
- Mid Florida Hematology and Oncology Center, Orange City · 距离 4 英里
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
招募中2/3 期
- Mid Florida Cancer Centers, Orange City · 距离 4 英里
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
招募中3 期
- Mid Florida Hematology and Oncology Center, Orange City · 距离 4 英里
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
招募中2/3 期
- Local Institution - 007-926-B, Daytona Beach · 距离 26 英里
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
招募中3 期
- Mid-Florida Hematology & Oncology Centers, P.A., Orange City · 距离 4 英里
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
招募中3 期
- Research Site, Orange City · 距离 4 英里
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
招募中1/2 期
- Mid Florida Hematology and Oncology Center, Orange City · 距离 4 英里
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
招募中2 期
- Mid Florida Hematology and Oncology Center, Orange City · 距离 4 英里
其他城市的 非小细胞肺癌试验
- Houston, TX145 项研究
- New York City, NY121 项研究
- Arlington, VA104 项研究
- Nashville, TN97 项研究
- Boston, MA90 项研究
- Los Angeles, CA87 项研究
- St. Louis, MO73 项研究
- Chicago, IL61 项研究
- Baltimore, MD60 项研究
- San Antonio, TX59 项研究
- Columbus, OH57 项研究
- Washington, DC55 项研究
Deltona的其他研究
- 肥胖症11 项研究
- 阿尔茨海默病10 项研究
- 2型糖尿病10 项研究
- 超重9 项研究
- 乳腺癌8 项研究
- 肺癌8 项研究
- 癌症（所有类型）7 项研究
- 转移性癌症5 项研究
- 慢性阻塞性肺病5 项研究
- 高血压5 项研究
- 黑色素瘤5 项研究
- 膝骨关节炎5 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。